Adebrelimab (SHR-1316)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Adebrelimab (SHR-1316), covering 2024-07-17 to 2025-10-02. Get the full timeline:
Most recent: Clinical Trial Update: A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma [Phase 2]